About Seer, Inc.

Seer is a life sciences company focused on capturing deep molecular insights from the proteome to enable novel insights and breakthroughs in the understanding of biology and disease.

Our novel Proteograph™ platform allows for the first-ever generation of proteomic information with high accuracy at a scale and speed not previously possible, complementing genomic and other health information, and with a goal of enabling research breakthroughs in the most challenging clinical problems, such as early disease detection.

We are advancing a portfolio of first-in-class products for research and clinical applications. Our technology can be utilized in strategic partnership with other key industry players to optimize their impact on drug discovery and development.

investors


Our Science

The Promise of Proteomics

Powerful, Untapped Disease Insights

The human proteome comprises more than 20,000 proteins.  Proteins carry out nearly every function of the human body.  The proteome can give us powerful insights into the presence and progression of disease that could be used by clinicians to drive treatment decisions. But, until now, there have been major technical and economic barriers to broad-scale proteomics analyses, leaving this rich resource of molecular information largely untapped for clinical purposes.

Molecular Information to Unlock Early Disease Detection

While genomic data has represented a massive step forward in helping us understand and more precisely treat disease, it has shown limited ability to detect early stage disease and track disease progression.  Proteomics reveals the relatively much larger body of data about health, including the future of health, and may hold the key to unlocking the elusive goal of early disease detection.

Translating Promise Into Reality

The promise of proteomics to yield critical disease data has long been known. But, until now, there have been major technical and economic barriers to broad-scale proteomics analyses. A primary obstacle has been the difficulty in managing the huge dynamic range of protein concentrations, with variations of 10-12 orders of magnitude from the most to the least abundant proteins in the plasma and other biologic fluids.

Research approaches have been developed to broadly analyze proteins across this dynamic range, but these approaches can take days to weeks to analyze a single sample. Our proprietary Proteograph technology platform is designed to overcome these challenges and to deliver on the promise of proteomics’ differentiated fundamental insights into disease mechanism and to thereby enable breakthrough applications such as pre-symptomatic detection of cancer, neurological and other diseases.

Novel Technology and Approach

Our Proteograph platform is designed to deliver proprietary proteomic information with high accuracy at a scale and speed not previously possible, complementing genomic and other health information, enabling first-in-class proteomics products for early disease detection and other applications.

Proteograph
Platform
Individual biomolecular fingerprints

  • Proprietary combination of novel biosensors that sample the proteome
  • Captures multiple data points for thousands of proteins from a single sample with high sensitivity and specificity, including unique proteins and protein-to-protein interactions
  • Yields broad and deep biomolecular fingerprint of health status and disease for each patient
Accelerate Basic and Clinical Research
Robust portfolio of proteomic products

  • Translate disease-specific, population-based data into real-world healthcare solutions
  • Advance a robust portfolio of research products to accelerate molecular biology and clinical research on disease mechanisms
  • With multiple ongoing clinical studies underway, our initial focus areas are oncology and neurology
Accelerate
R&D
Partnered product development

  • Strategically partner to apply the Proteograph platform for biomarker discovery, target identification, and accelerating clinical development

Collaborations to Enrich Data Sets

We will work with industry, government, and leading academic institutions to complement our activities in building internal data sets by accessing highly phenotyped patient samples.

Current collaborations

Nashville Biosciences, a subsidiary of Vanderbilt University Medical Center (oncology patient samples)

Brigham and Women’s Hospital (neurology patient samples)

Rich Information from Proteograph Platform

1

1

 

Detect subtle changes in the proteome when comparing healthy to disease states

2

2

Broadly sample the proteome for comprehensive analysis across the range of protein concentrations

3

3

Unveil biological insights from protein interactions and protein structural changes

Leadership

Seer’s leadership and scientific advisers include a multidisciplinary group of renowned experts in proteomics, data sciences, nanotechnology and precision medicine.
  • Omid Farokhzad, M.D.

    Chief Executive Officer

    Omid Farokhzad, M.D.

    Chief Executive Officer

    • Philip Ma, Ph.D.

      Chief Business Officer and President

      Philip Ma, Ph.D.

      Chief Business Officer and President

      • John Blume, Ph.D.

        VP, Research

        John Blume, Ph.D.

        VP, Research

        • Bill Manning, Ph.D.

          VP, Product Development

          Bill Manning, Ph.D.

          VP, Product Development

          • Greg Troiano, M.S. Eng.

            VP, Technology and Chief Engineer

            Greg Troiano, M.S. Eng.

            VP, Technology and Chief Engineer

            • Asim Siddiqui, Ph.D.

              VP, Software and Applications

              Asim Siddiqui, Ph.D.

              VP, Software and Applications

              • Omid Farokhzad, M.D.

                Chief Executive Officer

                Omid Farokhzad, M.D.

                Chief Executive Officer

                • David Hallal

                  Former Chief Executive officer at Alexion Pharmaceuticals

                  David Hallal

                  Former Chief Executive officer at Alexion Pharmaceuticals

                  • Robert Langer, Sc.D.

                    Institute Professor - Massachusetts Institute of Technology

                    Robert Langer, Sc.D.

                    Institute Professor - Massachusetts Institute of Technology

                    • Mark McClellan, Ph.D., M.D.

                      Founding Director of the Duke-Margolis Center for Health Policy

                      Mark McClellan, Ph.D., M.D.

                      Founding Director of the Duke-Margolis Center for Health Policy

                      • Terry McGuire

                        Founding Partner of Polaris Partners

                        Terry McGuire

                        Founding Partner of Polaris Partners

                        • David Singer

                          Managing Partner at Maverick Ventures

                          David Singer

                          Managing Partner at Maverick Ventures

                          • Robert Langer, Sc.D.

                            Chairman of Scientific Advisory Board

                            Robert Langer, Sc.D.

                            Chairman of Scientific Advisory Board

                            • Vivek Farias, Ph.D.

                              Chair of Data Committee

                              Vivek Farias, Ph.D.

                              Chair of Data Committee

                              • Philip Kantoff, M.D.

                                Chair of Clinical Committee

                                Philip Kantoff, M.D.

                                Chair of Clinical Committee

                                • Mostafa Ronaghi, Ph.D.

                                  Chair of Technology Committee

                                  Mostafa Ronaghi, Ph.D.

                                  Chair of Technology Committee

                                  • Erwin Böttinger, M.D.

                                    Professor of the Digital Engineering Faculty of HPI

                                    Erwin Böttinger, M.D.

                                    Professor of the Digital Engineering Faculty of HPI

                                    • Steve Carr, PH.D.

                                      Senior Director of Proteomics at Broad Institute of MIT and Harvard

                                      Steve Carr, PH.D.

                                      Senior Director of Proteomics at Broad Institute of MIT and Harvard

                                      • Charles Cantor, Ph.D.

                                        Emeritus Professor at Boston University

                                        Charles Cantor, Ph.D.

                                        Emeritus Professor at Boston University

                                        • Bradley Hyman, M.D., Ph.D.

                                          John B. Penny Professor of Neurology at Harvard Medical School

                                          Bradley Hyman, M.D., Ph.D.

                                          John B. Penny Professor of Neurology at Harvard Medical School

                                          • Wolfgang Parak, Ph.D.

                                            Professor of Physics and Chemistry at University of Hamburg

                                            Wolfgang Parak, Ph.D.

                                            Professor of Physics and Chemistry at University of Hamburg

                                            • Ralph Weissleder, M.D.

                                              Thrall Professor of Radiology at Harvard Medical School

                                              Ralph Weissleder, M.D.

                                              Thrall Professor of Radiology at Harvard Medical School

                                              Careers

                                              Life at Seer

                                              Seer is rapidly growing its team with accomplished individuals.  The Seer team is made up of talented and driven people who are united by their passion for creating a novel proteomic technology platform to discover new insights into biology and improve the lives of patients.  We value a collaborative environment where employees are empowered to excel.

                                              EMPLOYEE EXPERIENCE

                                              Seer is young, but we already have the foundations for an amazing culture – a dedicated and diverse team, passionate about making a difference for patients!

                                              Lily Paloma
                                              Sr. Manager, HR & Administration

                                              EMPLOYEE EXPERIENCE

                                              I am encouraged to push the boundaries of my own technical knowledge just as Seer pushes the boundaries in proteomics.

                                              Marwin Ko
                                              Associate Data Scientist

                                              EMPLOYEE EXPERIENCE

                                              I really feel that I have a voice at Seer. The company leaders, my colleagues and I are very much connected.

                                              Hongwei Xia
                                              Scientist, Formulations

                                              EMPLOYEE EXPERIENCE

                                              Seer is all about learning; the leaders constantly motivate us to challenge common wisdom and solve problems more effectively.

                                              Shadi Roshdiferdosi
                                              Scientist, Mass Spectrometry

                                              Open Positions

                                              See open positions at Seer

                                              For more information, contact careers@seer.bio

                                              Contact

                                              +1-650-453-0000, info@seer.bio
                                              3800 Bridge Parkway, Suite 102, Redwood City, CA  94065

                                              SEE MAP